Phase 1b clinical trial of IkT-148009: The Phase 1b study is a 3:1 randomized, placebo-controlled dose escalation trial evaluating the safety, tolerability, and pharmacokinetics of seven-day dosing of IkT-148009 at three escalating dose levels. The study is also assessing motor and non-motor function, gut motility, and measures of alpha-synuclein aggregate clearance as exploratory endpoints. In March, the Company presented data from the first cohort at the Alzheimer's & Parkinson's Diseases Conference (AD/PD™). Data demonstrated that the safety and tolerability profile in patients closely matched that of older healthy volunteers. Pharmacokinetics of IkT-148009 in volunteers and subjects was also similar, indicating that IkT-148009 pharmacology is consistent across the patient groups and penetrates the Central Nervous System. The Company expects to complete dosing of the Phase 1b study in the second quarter of 2022 and present full data at a medical meeting later this year.
Phase 1 dose escalation of IkT-148009 in older and elderly healthy volunteers: Inhibikase continues to evaluate IkT-148009 in older and elderly healthy volunteers as part of the Phase 1 study. The Company has completed dose escalation studies through 325 mg. To date, no clinically significant adverse events have been observed at any dose.
Phase 2a clinical study for IkT-148009 in patients with Parkinson's Disease: Inhibikase expects to dose the first patient in a Phase 2a study of IkT-148009 in untreated Parkinson's Disease in the second quarter of 2022, subject to agreements with the FDA. The 3:1 randomized, double-blind, twelve-week dosing trial will evaluate the safety and tolerability of three doses of IkT-148009 in up to 120 patients diagnosed with Parkinson's disease who have not yet progressed to the need for symptomatic therapy. The trial will also measure motor and non-motor function inside and outside of the brain as secondary endpoints and evaluate whether treatment with IkT-148009 leads to a reduction or clearance of pathogenic alpha-synuclein aggregates as exploratory endpoints.
Investigational New Drug application (IND) for IkT-001Pro for stable-phase Chronic Myelogenous Leukemia (CML): IkT-001Pro is the Company's prodrug formulation of Imatinib mesylate, designed as a potentially safer, better tolerated treatment for Imatinib-sensitive cancers such as stable-phase Chronic Myeloid Leukemia (CML). The Company is completing clinical batch manufacturing of pill formulated IkT-001Pro and conducting required stability studies and expects to submit the IND for IkT-001Pro in the second quarter of 2022. The Company expects to commence bioequivalence studies in accordance with the 505(b)(2) regulatory pathway agreements with the FDA.
Preclinical studies evaluating IkT-148009 in animal models of Multiple System Atrophy (MSA) in preparation for Phase 2 clinical studies: Inhibikase expects to report preclinical data studying IkT-148009 in at least one of two animal models of MSA prior to dosing of MSA patients. The studies are evaluating whether inhibition of the Abelson Tyrosine Kinase, or c-Abl, could have a therapeutic benefit in MSA. The potential role of c-Abl in the disease process was highlighted in the Company's recent publication published in the peer reviewed journal Neurobiology of Disease[1]. Depending on the preclinical results in animal models of MSA and subject to agreement with the FDA and equivalent regulatory bodies in the European Union, Inhibikase may advance IkT-148009 into a Phase 2a clinical study in the third quarter of 2022.
Successful Trading is the art of minimizing long term risk and maximizing capital allocation.
Recent IKT News
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/09/2024 06:41:37 PM
- Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension • GlobeNewswire Inc. • 05/09/2024 12:00:00 PM
- Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs • GlobeNewswire Inc. • 04/18/2024 08:30:00 PM
- Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension • GlobeNewswire Inc. • 04/03/2024 12:05:00 PM
- Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity • GlobeNewswire Inc. • 03/27/2024 08:15:20 PM
- Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders • GlobeNewswire Inc. • 03/07/2024 01:30:00 PM
- Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro • GlobeNewswire Inc. • 02/28/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 12:59:02 PM
- Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers • GlobeNewswire Inc. • 02/07/2024 12:55:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/01/2024 09:49:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 09:09:53 PM
- Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib • GlobeNewswire Inc. • 01/29/2024 02:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 09:31:03 PM
- Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli • GlobeNewswire Inc. • 01/16/2024 09:05:00 PM
- Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs • GlobeNewswire Inc. • 12/19/2023 01:30:00 PM
- Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro • GlobeNewswire Inc. • 12/04/2023 01:35:00 PM
- Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity • GlobeNewswire Inc. • 11/14/2023 09:30:06 PM
- Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023 • GlobeNewswire Inc. • 11/07/2023 02:28:32 PM
- Inhibikase Therapeutics to Report Second Quarter Financial Results on November 14, 2023 • GlobeNewswire Inc. • 11/07/2023 01:00:00 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 10/16/2023 09:24:04 PM
- Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing Enrollment • GlobeNewswire Inc. • 10/16/2023 11:00:27 AM
- Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy • GlobeNewswire Inc. • 10/04/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2023 03:23:58 PM
- Inhibikase Therapeutics Announces Development of Novel Formulation of risvodetinib • PR Newswire (US) • 08/24/2023 12:30:00 PM
- Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders • PR Newswire (US) • 08/22/2023 12:05:00 PM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM